LTB₄

LTB₄ Related Products (38):

By Type:	Pan (6) Selective (16)
By Effects:	Inhibitors (18) Agonists (2) Antagonists (17)

Cat. No.	Product Name	Effect	Purity

HY-19193

CP-105696	Antagonist	99.93%
CP-105696 is a potent and selective Leukotriene B₄ Receptor antagonist, with an IC₅₀ of 8.42 nM.

HY-15874

Fiboflapon	Inhibitor	99.50%
Fiboflapon (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (FLAP) inhibitor with a potency of 2.9 nM in FLAP binding, an IC₅₀ of 76 nM for inhibition of LTB4 in human blood.

HY-15744

LY255283	Antagonist	98.04%
LY255283 is a LTB₄ receptor (BLT2) antagonist, with an IC₅₀ of ~100 nM for [³H]LTB₄ binding to guinea pig lung membranes.

HY-13628

Etalocib	Antagonist	99.03%
Etalocib (LY293111), an orally active leukotriene B₄ receptor antagonist, inhibits the binding of [³H]LTB₄, with a K_i of 25 nM. Etalocib (LY293111) prevents LTB₄-induced calcium mobilization with an lC₅₀ of 20 nM. Etalocib (LY293111) induces apoptosis.

HY-114641A

BIIL-260 hydrochloride	Antagonist	99.90%
BIIL-260 hydrochloride is a potent and long-acting orally active leukotriene B(4) receptor LTB₄ antagonist, with anti-inflammatory activity. BIIL-260 hydrochloride interacts with the LTB₄ receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB₄ receptor on isolated human neutrophil cell membranes with K_i values of 1.7 nM.

HY-182422

CGS 23885	Inhibitor
CGS 23885 is an orally active 5-lipoxygenase (5-lipoxygenase) inhibitor. CGS 23885 reduces the production of 5-hydroxyeicosatetraenoic acid (5-hydroxyeicosatetraenoic acid), LTB₄, and LTC₄/D₄/E₄. CGS 23885 inhibits cell infiltration in rat pleurisy. CGS 23885 can be used in pleurisy-related research.

HY-180363

E 6080	Inhibitor
E 6080 is an orally active and selective 5-lipoxygenase (5-LOX) inhibitor with an IC₅₀ of 0.2 μM in rat basophilic leukemia cell. E 6080 shows potent inhibitory effects on the release of leukotrienes. E 6080 inhibits the bronchospasm induced by antigen (ovalbumin) inhalation in sensitized conscious guinea pigs. E 6080 can be used for the study of asthma.

HY-180411

SM-15178	Antagonist
SM-15178 is a potent, orally active and selective leukotriene B₄ (LTB₄) receptor antagonist with an IC₅₀ of 0.30 μM. SM-15178 attenuates LTB₄ (HY-107608)-induced neutrophil accumulation in mouse skin and bronchoconstriction in guinea pigs. SM-15178 emonstrates significant anti-inflammatory efficacy across multiple animal models of inflammation. SM-15178 can be used for the research of chronic inflammatory diseases such as inflammatory bowel disease, psoriasis, and asthma.

HY-113330

12S-HHT	Agonist	≥99.0%
12S-HHT (12(S)-HHTrE) is an enzymatic product of prostaglandin H₂ (PGH₂) derived from cyclooxygenase (COX)-mediated arachidonic acid metabolism. 12S-HHT is an endogenous ligand for BLT2 that fully activates BLT2 in vivo. 12S-HHT suppresses UV-induced IL-6 synthesis in keratinocytes, exerting an anti-inflammatory activity.

HY-111806

3,7,4'-Trihydroxyflavone	Inhibitor	99.11%
3,7,4'-Trihydroxyflavone (5-Deoxykampferol) is a flavonoid compound that can be isolated from the stems of Rhus javanica var. roxburghiana. 3,7,4'-Trihydroxyflavone has the effect of cleaving DNA in the presence of copper ions. 3,7,4'-Trihydroxyflavone also has anti-inflammatory and antioxidant activities and can scavenge various reactive oxygen species (ROS) and reactive nitrogen species (RNS).

HY-112737

LY223982	Inhibitor	99.65%
LY223982 is a potent and specific inhibitor of leukotriene B4 receptor, with an IC₅₀ of 13.2 nM against [³H]LTB4 binding to LTB4 receptor.

HY-19304

Amelubant	Antagonist	98.45%
Amelubant (BIIL 284) is a potent, oral and long acting LTB₄ receptor antagonist, negligibly binds to LTB₄ receptor, with K_is of 221 nM and 230 nM in vital cells and membranes. Amelubant (BIIL 284) is a proagent of active metabolites BIIL 260 and BIIL 315. Anti-inflammatory activity.

HY-15874A

Fiboflapon sodium	Inhibitor	98.51%
Fiboflapon sodium (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (FLAP) inhibitor with a potency of 2.9 nM in FLAP binding, an IC₅₀ of 76 nM for inhibition of LTB4 in human blood.

HY-14165

Veliflapon	Inhibitor	99.31%
Veliflapon (BAY X 1005; DG-031) is an orally active and selective 5-lipoxygenase activating protein (FLAP) inhibitor. Veliflapon inhibits the synthesis of the leukotrienes B4 and C4.

HY-113483

20-Carboxy-Leukotriene B4	Inhibitor	98.53%
20-Carboxy-Leukotriene B4 (20-COOH LTB4) is a metabolite of Leukotriene B4 (LTB4; HY-107608). 20-Carboxy-Leukotriene B4 binds to the BLT1 receptor with high affinity. 20-Carboxy-Leukotriene B4 inhibits LTB4-mediated neutrophil responses (migration, degranulation, leukotriene biosynthesis).

HY-112741

SB-209247	Antagonist	99.33%
SB-209247 is a selective, high affinity and orally active leukotriene B4 (LTB4) receptor antagonist with a K_i of 0.78 nM. SB-209247 blocks LTB4-induced Ca²⁺ mobilization with an IC₅₀ of 6.6 nM. SB-209247 shows a potent anti-inflammatory activity.

HY-W341962

Halometasone	Inhibitor	98.47%
Halometasone is a corticosteroid compound that can reduce the expression of serum leukotriene B4 (LTB4) and thymic stromal lymphopoietin (TSLP). Halometasone can be used in research on psoriasis and eczematous skin diseases.

HY-122124

CAY10583	Agonist	99.9%
CAY10583 is a potent and selective full Leukotriene B4 receptor type 2 (BLT2) agonist. CAY10583 directly promotes keratinocyte migration in vitro and accelerates wound closure in vivo. CAY10583 is a promising pharmaceutical agent for diabetic wounds.

HY-U00252

ONO4057	Antagonist	99.9%
ONO4057 is a Leukotriene B₄ receptor antagonist, with an IC₅₀ of 0.7±0.3 μM.

HY-N4267

Yangambin	Inhibitor	98.27%
Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC₅₀ of 29.7 μM and a K_i of 17.1 μM against human UGT1A1, and an IC₅₀ of 56.5 μM and a K_i of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB₄-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca²⁺ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases.

Name
Email *

	Sorry, but the email address you supplied was invalid.